BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)
I'm PortAI, I can summarize articles.
BTIG analyst Jeet Mukherjee reiterated a Buy rating on Monopar Therapeutics Inc with a $104 price target. The stock closed at $87.01, and analysts have a consensus Strong Buy rating with a $110.33 price target, suggesting a 26.80% upside. Barclays also reiterated a Buy rating with a $125 target. Mukherjee, a 4-star analyst, has a 19.4% average return and a 71.43% success rate.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments